Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

Among patients with type 2 diabetes and peripheral artery disease or foot ulcers, the use of semaglutide is linked to a ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

The market for generic GLP-1 weight loss drugs in Canada is set to open up, and Hims & Hers is ready to jump in.  | Novo ...

A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Weight loss injections can help people lose more weight than with other methods of weight loss, including lifestyle changes ...

Women and older adults taking the anti-obesity drug semaglutide may be at higher risk for muscle loss, but higher protein ...

The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by rising obesity and type 2 diabetes incidences, the ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

CoQ10 may interact with certain medications, causing side effects or making them less effective. Find out if you shouldn't ...

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?